Disruption of Sema3A/Plexin‐A1 inhibitory signalling in oligodendrocytes as a therapeutic strategy to promote remyelination

Current treatments in multiple sclerosis (MS) are modulating the inflammatory component of the disease, but no drugs are currently available to repair lesions. Our study identifies in MS patients the overexpression of Plexin‐A1, the signalling receptor of the oligodendrocyte inhibitor Semaphorin 3A....

Descripción completa

Detalles Bibliográficos
Autores principales: Binamé, Fabien, Pham‐Van, Lucas D, Spenlé, Caroline, Jolivel, Valérie, Birmpili, Dafni, Meyer, Lionel A, Jacob, Laurent, Meyer, Laurence, Mensah‐Nyagan, Ayikoé G, Po, Chrystelle, Van der Heyden, Michaël, Roussel, Guy, Bagnard, Dominique
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6835579/
https://www.ncbi.nlm.nih.gov/pubmed/31566924
http://dx.doi.org/10.15252/emmm.201910378

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6835579/
https://www.ncbi.nlm.nih.gov/pubmed/31566924
http://dx.doi.org/10.15252/emmm.201910378

Ejemplares similares